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Introduction 
This Comment provides a summary of the Supreme Court’s most 
recent decision analyzing the bounds of patent eligibility: Mayo 
Collaborative Services v. Prometheus Laboratories, Inc.1 In this 
March 2012 decision, the Court significantly departed from the Federal 
Circuit’s2 prevalent use of the “machine-or-transformation test” for 
determining the limits of patentable subject matter.3 The Court 
unanimously reversed the Federal Circuit’s decision in favor of 
 
1. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289 
(2012). 
2. The United States Court of Appeals for the Federal Circuit was established 
in 1982 and has nationwide jurisdiction over patent law appeals arising from 
any United States District Court. Court Jurisdiction, U.S. Ct. Appeals 
for Fed. Circuit, http://www.cafc.uscourts.gov/the-court/court-juris 
diction.html (last visited Oct. 27, 2012).  
3. See Mayo, 132 S. Ct. at 1303 (precluding the “machine-or-transformation” 
test from trumping the “law of nature” exclusion). 
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Prometheus and found that the correlation between thiopurine drug 
dosage and a patient’s subsequent metabolic response amounted to an 
unpatentable law of nature.4 
The synopsis herein is intended as a general overview of subject 
matter that is patentable under 35 U.S.C. § 101, as well as the impact 
of the Mayo decision on patent examination and patent eligibility.5 
Thus, this Comment is predominantly intended for nonspecialists, as 
it does not scrutinize the scientific principles of Prometheus’s patents 
or the decision’s overall impact on the field of medical technology.6 
Part I of this Comment provides a brief introduction to the statutory 
bounds of patentable subject matter under 35 U.S.C. § 101. Part II 
summarizes the patents at issue in Mayo and the complex history of 
Prometheus’s dispute. That section goes on to clarify the meaning and 
impact of the Court’s landmark interpretation regarding the patent 
eligibility of natural laws. Finally, Part III discusses the effect of the 
Mayo ruling on patent examination procedures at the United States 
Patent and Trademark Office and the holding’s potential impact on 
pending Federal Circuit cases. 
I. Patent Eligibility: The Merger of Statutory 
Guidance Under 35 U.S.C. § 101 and  
Patent Law Precedent 
Under 35 U.S.C. § 101, a patent is conferred upon “[w]hoever invents 
or discovers any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof,” 
subject to the additional requirements of the Patent Act.7 In a broad 
sense, § 101 acts as a threshold to patentability by distinguishing 
between the discovery of an existing principle versus the creation of an 
original invention. Of course, the subsequent questions of whether an 
 
4. Id. at 1292, 1305. 
5. Given the sweeping reform to United States patent law that will stem 
from the March 2013 implementation of the Leahy-Smith America 
Invents Act, it is important to note that the text of 35 U.S.C. § 101 will 
remain unchanged. The only mention of § 101 in Leahy-Smith notes 
that “[n]othing in this section shall be construed as amending or 
interpreting categories of patent-eligible subject matter set forth under 
section 101 of title 35, United States Code.” Leahy-Smith America 
Invents Act, Pub. L. No. 112-29, § 18(e), 125 Stat. 284, 331 (2011).  
6. Following oral arguments in the Mayo decision, SCOTUSblog reported 
that “[t]he Supreme Court finished an hour of oral argument . . . on a 
highly complex patent case, seemingly as deep in confusion at the end as 
at the beginning . . . .” Lyle Denniston, Argument Recap: For Want of 
a Good Hypothetical, SCOTUSblog (Dec. 7, 2011, 4:43 PM), 
http://www.scotusblog.com/2011/12/argument-recap-for-want-of-a-good 
-hypothetical. 
7. 35 U.S.C. § 101 (2006). 
Case Western Reserve Law Review·Volume 63·Issue 2·2012 
An Overview of Patentable Subject Matter and the Effect of Mayo 
637 
invention is novel,8 nonobvious,9 and adequately filed10 are critical 
inquiries that encompass the bulk of patent examination and 
litigation.11 But in order to warrant further examination, an inventor 
must first overcome the subject matter eligibility threshold of § 101.12 
The underlying premise of patent law is to incentivize progress 
and innovation by rewarding an inventor with the right to exclude 
others from capitalizing upon his advancements for a particular period 
of time.13 To grant an inventor a monopoly over a general scientific 
rule would directly counteract patent law’s purpose of promoting 
innovation.14 Thus, even celebrated breakthroughs such as Newton’s 
law of gravity and Einstein’s revelation that E=mc2 would not 
constitute patentable subject matter.15 Although such discoveries were 
previously unknown and groundbreaking scientific advancements, the 
concepts as a whole describe existing natural laws and do not satisfy 
the patentability requirements of § 101.16 
Thus, the policy rationale behind subject matter inquiries—and 
patent law as a whole—is to balance an individual’s right to capitalize 
upon his invention against the risk of hindering innovation by 
imposing an effective monopoly through patenting.17 The Mayo Court 
 
8. 35 U.S.C. § 102. 
9. 35 U.S.C. § 103. 
10. 35 U.S.C. § 112. 
11. Although § 101 contains the somewhat misleading “new and useful” 
language, the question of whether an invention satisfies the threshold of 
patentable subject matter discussed herein is wholly separate from the 
subsequent considerations of statutory novelty and nonobviousness. See 
Diamond v. Diehr, 450 U.S. 175, 190–91 (1981) (noting that an 
invention may fail either the nonobvious or novelty requirements but 
still satisfy the threshold requirement for patent protection under 
§ 101). 
12. Id. 
13. Diamond v. Chakrabarty, 447 U.S. 303, 307 (1980). Patent law in the 
United States originates from Congress’s constitutional power to 
“promote the Progress of Science and useful Arts, by securing for 
limited Times to Authors and Inventors the exclusive Right to their 
respective Writings and Discoveries.” U.S. Const. art. I, § 8, cl. 8. 
14. See Mayo Collaborative Servs. v. Prometheus Labs. Inc., 132 S. Ct. 
1289, 1293 (2012) (“[M]onopolization of [scientific] tools through the 
grant of a patent might tend to impede innovation more than it would 
tend to promote it.”). 
15. Id.  
16. See Diehr, 450 U.S. at 185 (“A principle, in the abstract, is a 
fundamental truth; an original cause; a motive; these cannot be 
patented, as no one can claim in either of them an exclusive right.” 
(quoting Le Roy v. Tatham, 55 U.S. (14 How.) 156, 175 (1853))). 
17. Mayo, 132 S. Ct. at 1293. 
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described the balance between rewarding innovation and protecting 
the public domain: 
Patent protection is, after all, a two-edged sword. On the one 
hand, the promise of exclusive rights provides monetary 
incentives that lead to creation, invention, and discovery. On 
the other hand, that very exclusivity can impede the flow of 
information that might permit, indeed spur, invention, by, for 
example, raising the price of using the patented ideas once 
created, requiring potential users to conduct costly and time-
consuming searches of existing patents and pending patent 
applications, and requiring the negotiation of complex licensing 
arrangements.18 
Both courts and commentators frequently cite the notion that an 
inventor may patent “anything under the sun that is made by man.”19 
In practice, though, such a broad statement is ambiguous and 
somewhat misleading. Defining the precise bounds of what constitutes 
a patentable “process, machine, manufacture, or composition of 
matter” under § 101 has been a source of considerable debate, given 
the vague language of the statute and the fast pace of scientific 
advancements. Although not explicit in the language of § 101, courts 
are bound by the fundamental precedent that “laws of nature, 
physical phenomena, and abstract ideas” are not patentable subject 
matter.20 The purpose of these exceptions is to bar an inventor from 
monopolizing discoveries that are “manifestations of . . . nature, [that 
must remain] free to all men and reserved exclusively to none.”21 
Although laws of nature, physical phenomena, and abstract ideas 
are never patentable, the boundaries that these exceptions encompass 
are frequently less straightforward than the aforementioned examples 
of attempting to patent gravity or the law of relativity. In Diamond 
v. Diehr, the Supreme Court noted that “‘a process is not 
unpatentable simply because it contains a law of nature or a 
mathematical algorithm,’” because, in fact, “an application of a law of 
 
18. Id. at 1305. 
19. See Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (noting that the 
Committee Reports of the 1952 Patent Act provide the origin of the 
famous “anything under the sun” language); Helen M. Berman & 
Rochelle C. Dreyfuss, Reflections on the Science and Law of Structural 
Biology, Genomics, and Drug Development, 53 UCLA L. Rev. 871, 873 
(2006) (discussing the Supreme Court’s broad “anything under the sun” 
language and its implications for patent law). 
20. Chakrabarty, 447 U.S. at 309, 315 (“Congress has performed its 
constitutional role in defining patentable subject matter in § 101; we 
perform ours in construing the language Congress has employed.”). 
21. Id. at 309 (first alteration in original) (quoting Funk Bros. Seed Co. v. 
Kalo Inoculant Co., 333 U.S. 127, 130 (1948)). 
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nature or mathematical formula to a known structure or process may 
well be deserving of patent protection.”22 In Diehr, the Court 
analyzed whether a mathematical formula, the Arrhenius equation, 
was a patentable matter within a process for curing synthetic 
rubber.23 The Court held that although the “Arrhenius equation is not 
patentable in isolation,” the inventors merely incorporated the 
equation to calculate optimal cure time, and the patent as a whole 
provided an innovative, new approach to the entire precision molding 
process.24 Thus, the Court held that the “process [was] at the very 
least not barred at the threshold by § 101.”25  
The boundary that separates prohibited recitations of natural 
laws from permissible applications of the same natural laws is unclear 
and thus a prime target for litigation. Mayo was the most recent 
effort by the Court to clarify where, precisely, this boundary exists.26 
II. Opposite Sides of a Bright-Line Rule:  
The Conflicting Conclusions of the Federal Circuit 
and the Supreme Court 
Prometheus was the exclusive licensee of U.S. Patent No. 
6,355,62327 and U.S. Patent No. 6,680,302.28 In essence, the process 
protected by the patents instructed medical personnel to first 
administer a thiopurine drug to a patient and thereafter to measure 
the metabolites in a sample of the patient’s blood.29 The medical 
 
22. Diamond v. Diehr, 450 U.S. 175, 187 (1981) (first emphasis added) 
(quoting Parker v. Flook, 437 U.S. 584, 590 (1978)). Diehr was decided 
in the year following Chakrabarty, and together the two cases redefined 
the methods of analyzing subject matter patentability. See id. at 181–82 
(discussing the history of subject matter patentability and citing 
Chakrabarty)). 
23. Id. at 177. 
24. Id. at 188. 
25. Id. 
26. See Mayo Collaborative Servs. v. Prometheus Labs. Inc., 132 S. Ct. 
1289, 1297 (2012) (“To put the matter more precisely, do the patent 
claims add enough to their statements of the correlations to allow the 
processes they describe to qualify as patent-eligible processes that apply 
natural laws?”). 
27. Method of Treating IBD/Crohn’s Disease & Related Conditions 
Wherein Drug Metabolite Levels in Host Blood Cells Determine 
Subsequent Dosage, U.S. Patent No. 6,355,623 (filed Apr. 8, 1999). 
28. Methods of Optimizing Drug Therapeutic Efficacy for Treatment of 
Immune-Mediated Gastrointestinal Disorders, U.S. Patent No. 6,680,302 
(filed Dec. 27, 2001).  
29. Adam Liptak, Justices Back Mayo Clinic Argument on Patents, N.Y. 
Times, Mar. 21, 2012, at B3.  
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researchers behind the invention calculated the optimal ratios of the 
drug dosage to the patient’s blood sample in order to maximize the 
dosage’s efficiency while minimizing the risk of overdose.30 Thus, the 
final aspect of the patented process indicated that a doctor should 
adjust the amount of thiopurine subsequently administered to the 
patient based on these precise ratios.31 
Thiopurine drugs are typically administered to treat 
gastrointestinal disorders such as ulcerative colitis and Crohn’s 
disease.32 Prior to the patents’ claimed discoveries, researchers in the 
field understood the general relationship between the dosage of 
thiopurine relative to the amount of metabolites in a patient’s blood; 
however, medical researchers had not established any sort of precise 
test to evaluate the correlation or determine the likely effectiveness of 
the medicine.33 
Prometheus developed the patented research into tangible 
diagnostic tests for medicinal use.34 As the exclusive licensee of the 
technology, Prometheus sold the diagnostic tests to Mayo Medical 
Laboratories and Mayo Collaborative Services.35 In June 2004, Mayo 
announced the company’s intention to begin marketing its own 
diagnostic test with similar—though not precisely the same—
thiopurine dosage parameters, and thus Mayo effectively terminated 
its relationship with Prometheus.36 Immediately following Mayo’s 
announcement, Prometheus Laboratories sued for patent infringement 
on June 15, 2004.37 
A. Mayo’s Inescapable Ties to the  
Parallel Bilski v. Kappos Proceedings 
Prometheus’s lengthy, and ultimately unsuccessful, effort to 
uphold their patents’ validity was riddled with unusual procedural 
twists. Initially, the United States District Court for the Southern 
 
30. Id. 
31. More precisely, the patents claimed the diagnostic correlation between 
the dosage of thiopurine and the concentration of 6-TG or 6-MMP 
metabolite in a patient’s blood. Mayo, 132 S. Ct. at 1295. 
32. Id. at 1294–95.  
33. Id. at 1295. 
34. Id. The Prometheus Laboratories website features various diagnostic 
tests sold by the company. See Products and Services: Diagnostics, 
Prometheus, http://www.prometheuspatients.com/Products_Diagnost 
ics.asp (last visited Dec. 19, 2012). 
35. Mayo, 132 S. Ct. at 1295. 
36. Prometheus Labs., Inc. v. Mayo Collaborative Servs., No. 04cv1200 JAH 
(RBB), 2008 WL 878910, at *1 (S.D. Cal. Mar. 28, 2008). 
37. Id. 
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District of California found the Prometheus patents to be invalid and 
granted summary judgment in favor of Mayo.38 The court concluded 
that the patents simply claimed correlations between thiopurine levels 
and the drug’s therapeutic effects, and thus the patents were no more 
than a recitation of data-gathering steps for evaluating natural 
phenomena.39 
It is crucial to emphasize that the District Court’s decision came 
in March 2008.40 Given the infrequency of § 101 patent eligibility 
questions reaching the Supreme Court, it is important to note that 
the short time span of 2008 through 2012 included two important 
§ 101 patent litigations running in parallel to one another.41 The first, 
Mayo, questioned the patentability of laws of nature; the second, 
Bilski v. Kappos, questioned the patentability of an abstract idea.42 
At nearly the precise midpoint of the one year span between Mayo’s 
District Court decision and subsequent Federal Circuit appeal, the 
Federal Circuit in Bilski declared the so-called “machine-or-
transformation test” as the definitive mechanism for determining a 
patent’s § 101 eligibility.43 The machine-or-transformation test is a 
test of whether an invention for a process or method “is (1) tied to a 
particular machine or apparatus, or (2) transforms a particular article 
to a different state or thing.”44 
Thus, on the aforementioned appeal by Prometheus in September 
2009, the Federal Circuit reversed the District Court’s ruling based on 
their use of Bilski’s machine-or-transformation test as a bright-line 
rule.45 The Federal Circuit held that the steps of administering a 
certain amount of the thiopurine drug in relationship to the patient’s 
metabolite levels were “transformative methods of treatment, not 
 
38. Id. 
39. Id. at *6 
40. Id. at *1. 
41. There is the possibility of a third § 101 opinion reaching the Court in an 
upcoming term. For further discussion, see infra Part III.B.  
42. See In re Bilski, 545 F.3d 943, 949 (Fed. Cir. 2008) (noting that the 
patent at issue covered a business method process for evaluating risk in 
price changes, which necessitated the subject matter analysis of abstract 
ideas), aff’d sub nom. Bilski v. Kappos, 130 S. Ct. 3218 (2010). 
43. Id. at 956 (reaffirming in October 2008 “that the machine-or-
transformation test properly applied, is the governing test for 
determining patent eligibility of a process under § 101.”). 
44. Memorandum from John J. Love, Deputy Comm’r for Patent 
Examination Policy, on Guidance for Examining Process Claims in view 
of In re Bilski (Jan. 7, 2009), available at http://www.uspto.gov/ 
patents/resources/methods/bilski_guidance_memo.pdf. 
45. Prometheus Labs., Inc. v. Mayo Collaborative Servs., 581 F.3d 1336, 
1349–50 (Fed. Cir. 2009). 
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correlations,” because “[t]he inventive nature of the claimed methods 
stems . . . from the application of a natural phenomenon in a series of 
transformative steps comprising particular methods of treatment.”46  
Bilski reached the Supreme Court first, and the Court reassessed 
the importance of the machine-or-transformation test, declaring that 
it was simply “a useful and important clue” in evaluating patent 
eligibility, rather than the bright-line definitive rule for subject matter 
patentability.47 The next day, the Court granted certiorari in Mayo 
and summarily reversed and remanded in light of Bilski.48  
When Mayo subsequently reached the Federal Circuit for a second 
time in 2010, the case was closely watched for its potentially 
widespread impact on the “personalized medicine” field.49 However, 
rather anticlimactically, the Federal Circuit once again relied on the 
machine-or-transformation test and reaffirmed its decision in favor of 
Prometheus.50 The Federal Circuit elaborated upon the transformative 
aspect of the patented invention:  
Determining the levels of 6–TG or 6–MMP in a subject 
necessarily involves a transformation. Some form of 
manipulation, such as the high pressure liquid chromatography 
method specified in several of the asserted dependent claims or 
some other modification of the substances to be measured, is 
necessary to extract the metabolites from a bodily sample and 
determine their concentration. As stated by Prometheus’s 
expert, “at the end of the process, the human blood sample is 
no longer human blood; human tissue is no longer human 
tissue.” That is clearly a transformation.51 
The Federal Circuit’s opinion did take care to repeatedly refer to the 
machine-or-transformation test as a “useful clue” rather than a 
 
46. Id. at 1349 (emphasis added). 
47. Bilski v. Kappos, 130 S. Ct. 3218, 3227 (2010). 
48. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 130 S. Ct. 3543 
(2010) (mem.), vacating and remanding 581 F.3d 1336 (Fed. Cir. 2009). 
Bilski was decided on June 28 and certiorari was granted and the 
judgment vacated and remanded in Mayo on June 29. 
49. Andrew Pollack, Court Backs Patents for Diagnostic Tests, N.Y. Times 
(Dec. 17, 2010, 5:12 PM), http://prescriptions.blogs.nytimes.com/ 
2010/12/17/court-backs-patents-for-diagnostic-tests. 
50. Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 
1359 (Fed. Cir. 2010). 
51. Id. at 1357 (citing Decl. of Dr. Yves Théorêt in Support of Prometheus 
Labs. Inc.’s Opposition to Defendants’ Motion for Summary Judgment 
of Patent Invalidity under 35 U.S.C. § 101 ¶ 6, Prometheus Labs., Inc. 
v. Mayo Collaborative Servs., No. 04-CV-1200 JAH (RBB) (S.D. Cal. 
Mar. 29, 2007) (No. 528-2)). 
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bright-line rule; however, the court’s opinion seemed to indicate that 
the Bilski holding did little to change the Federal Circuit’s prior 
ruling.52 
Following this second defeat in the Federal Circuit, Mayo once 
again filed a petition for certiorari, which was granted.53 The final 
hurdle in the winding procedural road to the Supreme Court came 
just prior to oral arguments in December 2011, when Prometheus 
revealed to the Court that Nestle had purchased the company the 
prior July.54 Though seemingly unrelated to the medical patents at 
issue, it emerged that Justice Breyer’s wife owned stock in Nestle, 
which would have necessitated his recusal from the proceedings.55 
However, the Nestle stock was sold on the morning of December 7, 
which permitted Justice Breyer to be present that afternoon for oral 
arguments and to go on to write the Court’s opinion.56 
B. A Unanimous Decision: Analyzing Application 
Rather than Transformation 
Though propelled by dual Federal Circuit victories, Prometheus 
was soundly defeated at the Supreme Court in a 9–0 decision on 
March 20, 2012.57 In a broad sense, the Court agreed with the original 
ruling of the California District Court, holding that the Prometheus 
patents simply described the relationship between thiopurine dosage 
and patent side effects, which is a natural law and therefore 
unpatentable subject matter under 35 U.S.C. § 101.58 
Following the examples of each of the preceding courts, the 
Supreme Court relied on the following language from the ’623 patent 
as the representative scope of the invention for analyzing 
patentability:  
A method of optimizing therapeutic efficacy for treatment of an 
immune-mediated gastrointestinal disorder, comprising: 
 
52. See id. at 1355 (“Thus, the Court did not disavow the machine-or-
transformation test. And, as applied to the present claims, the ‘useful and 
important clue, an investigative tool,’ leads to a clear and compelling 
conclusion . . . that the present claims pass muster under § 101.”). 
53. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 131 S. Ct. 3027 
(2011) (granting certiorari). 
54. Liptak, supra note 29, at B3. 
55. Id. 
56. Id. 
57. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 
1292, 1305. 
58. Id. at 1305. 
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(a) administering a drug providing 6-thioguanine to a subject 
having said immune-mediated gastrointestinal disorder; and 
(b) determining the level of 6-thioguanine in said subject having 
said immune-mediated gastrointestinal disorder, 
wherein the level of 6-thioguanine less than about 230 pmol per 
8×108 red blood cells indicates a need to increase the amount of 
said drug subsequently administered to said subject and 
wherein the level of 6-thioguanine greater than about 400 pmol 
per 8×108 red blood cells indicates a need to decrease the 
amount of said drug subsequently administered to said subject.59 
Justice Breyer emphasized that the patents simply stated “that if 
the levels of 6–TG in the blood (of a patient who has taken a dose of 
a thiopurine drug) exceed about 400 pmol per 8×108 red blood cells, 
then the administered dose is likely to produce toxic side effects.”60 
Thus, the patents merely contained a procedural recitation, 
instructing doctors to (1) measure the current level of the relevant 
metabolite through any available means, (2) use the laws of nature to 
calculate the patient’s toxicity limits, and (3) reconsider the 
thiopurine dosage in light of the natural law.61 In the above three 
succinct steps, Justice Breyer explained that the patents lacked the 
critical element of an application of a law of nature and instead 
amounted to no more than a recitation of natural laws. 
The Court chided the Prometheus patents for encompassing 
“nothing significantly more than an instruction to doctors to apply 
the applicable laws [of nature] when treating their patients” and using 
only “what is [a] well-understood, routine, conventional activity, 
previously engaged in by those in the field.”62 The Court’s opinion gave 
credence to the “transformative” aspect of the machine-or-transformation 
test by noting that the central issue before the Court hinged on “whether 
the . . . processes have transformed . . . unpatentable natural laws into 
patent-eligible applications of those laws.”63 But the Court did not accept 
the Federal Circuit’s reliance on the process steps of high-pressure liquid 
 
59. Id. at 1295 (citing claim 1 of Method of Treating IBD/Crohn’s Disease 
& Related Conditions Wherein Drug Metabolite Levels in Host Blood 
Cells Determine Subsequent Dosage, U.S. Patent No. 6,355,623 col. 20 
ll. 10–20 (filed Apr. 8, 1999)). The Court clarified that “[f]or present 
purposes we may assume that the other claims in the patents do not 
differ significantly from claim 1.” Id. 
60. Id. at 1296–97. 
61. Id. at 1299.  
62. Id. at 1292, 1298. 
63. Id. at 1294. 
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chromatography and other lab work that “transforms” the patient’s 
blood sample to a different “thing” in order to extract and measure 
metabolites.64 The Court held that the actions of administering the 
thiopurine drug and subsequently measuring the metabolites obvi-
ously constituted necessary interventions; however, the invention as a 
whole simply encompassed a patient’s internal response to a dose of 
medicine, which occurs entirely independent of outside involvement.65  
III. The Impact of Mayo on Future  
Patent Examination and Litigation 
The U.S. Patent and Trademark Office (USPTO) governs all 
aspects of applying for, examining, and obtaining a patent. The 
USPTO responded almost immediately to the Mayo holding and issued 
a short brief to update patent examiners on the changes to their § 101 
analysis on March 21, 2012, one day after the Court’s decision in 
Mayo.66 The USPTO then further updated the guidance measures in 
July with a lengthier Guidance Memo.67 Thus, the USPTO has clearly 
taken proactive measures to ensure the widespread precedential impact 
of the Mayo holding on subject matter eligibility inquiries. There is, 
however, some uncertainty as to whether the Federal Circuit will be as 
willing to comply. 
A. New 35 U.S.C. § 101 Patent Examination Procedures  
in the Wake of the Mayo Ruling 
In general, patents are either granted or denied as a result of 
ongoing communications between an inventor and an examiner at the 
USPTO. Patent applications are reviewed by the examiner for 
compliance with the Patent Act, and the examiner is required to 
interpret the application in the broadest terms that would be 
reasonable to a person of ordinary skill in the art.68 Thus, the process 
 
64. Prometheus Labs., Inc. v. Mayo Collaborative Servs., 628 F.3d 1347, 
1355, 1357 (Fed. Cir. 2010). 
65. Mayo, 132 S. Ct. at 1297. 
66. Memorandum from Andrew H. Hirshfeld, Assoc. Comm’r for Patent 
Examination Policy, on the Supreme Court Decision in Mayo 
Collaborative Services v. Prometheus Laboratories, Inc. (Mar. 21, 2012), 
available at http://www.uspto.gov/patents/law/exam/mayo_prelim_ 
guidance.pdf. 
67  See infra Part III.A. 
68. See Memorandum from Andrew H. Hirshfeld, Assoc. Comm’r for Patent 
Examination Policy, on the 2012 Interim Procedure for Subject Matter 
Eligibility Analysis of Process Claims Involving Laws of Nature 2 (July 
3, 2012), available at http://www.uspto.gov/patents/law/exam/2012 
_interim_guidance.pdf [hereinafter 2012 Guidance Memo] (“Establish the 
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of patenting an invention is, in essence, a back-and-forth 
“conversation” between the applicant and examiner to accept, reject, 
amend, and clarify the description and wording of the invention in 
search of patentability. Any granted patents, including the two at 
issue in Mayo, have a presumption of validity since they were 
approved by a USPTO examiner.69  
On July 3, 2012, the USPTO issued a memorandum outlining the 
new analytic methods patent examiners should use in evaluating 
patentable subject matter in light of the Court’s holding in Mayo.70 
The new Guidance Memo sets forth revised procedures with the 
specific intention that if Prometheus’s patent applications were before 
an examiner today, they would not be approved as patentable subject 
matter. 
The new USPTO criterion sets forth a three-prong inquiry that 
analyzes subject matter eligibility in a question and answer format:  
(1) Is the . . . invention directed to a process, defined as an act, 
or a series of acts or steps? . . .  
(2) Does the [invention] focus on use of a law of nature, a 
natural phenomenon, or naturally occurring relation or 
correlation (collectively referred to as a natural principle 
herein)? (Is the natural principle a limiting feature of the 
[invention]?) . . . 
(3) Does the [invention] include additional elements/steps or a 
combination of elements/steps that integrate the natural 
principle into the . . . invention such that the natural 
principle is practically applied, and [is] sufficient to ensure 
that the [invention] amounts to significantly more than the 
natural principle itself? (Is it more than a law of nature 
[plus] the general instruction to simply “apply it”?)71 
Inquiry 1 simply serves as a threshold question regarding whether 
Mayo is applicable to the type of invention disclosed in the patent 
application. Inquiry 2 then describes the category of potentially 
 
broadest reasonable interpretation of the claims when read in light of the 
specification and from the view of one of ordinary skill in the art.”).  
69. See 35 U.S.C. § 282 (2006). 
70. 2012 Guidance Memo, supra note 68. The 2012 Guidance Memo 
superseded the analytic methods from the previous March 21 
memorandum discussed in the text accompanying note 66. 
71. 2012 Guidance Memo, supra note 68, at 2. The memo indicates that the 
guidance therein is interim, while the USPTO awaits issuing 
comprehensive guidance after the Court’s reconsideration of the Myriad 
and Ultramercial cases discussed infra Part III.B. See id. at 1. 
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“dangerous” subject matter that could warrant further examination.72 
The Guidance Memo clarifies inquiry 2 by defining a natural principle 
to be “the handiwork of nature [that] occurs without the hand of 
man.”73 The USPTO gives the examples of the disinfecting property 
of sunlight or the correlation between blood glucose levels and 
diabetes as rather simplistic versions of natural principles.74 As 
discussed previously, if the patent encompasses an abstract idea 
rather than a natural principle, then Bilski governs the analysis rather 
than Mayo.75 An abstract idea under Bilksi includes, for example, 
mental steps or plans for performing an action.76 
Inquiry 3 is the defining question at the heart of Mayo. If 
satisfied, the invention is eligible subject matter.77 The Guidance 
Memo instructs that “[a] bare statement of a naturally occurring 
correlation, albeit a newly discovered natural correlation or very 
narrowly confined correlation, would fail [inquiry 3].”78 The USPTO 
directly quotes the Mayo holding throughout the memo, noting that 
“[a]dding steps to a natural biological process that only recite well-
understood, routine, conventional activity previously engaged in by 
researchers in the field would not be sufficient” to satisfy the subject 
matter requirements of § 101.79  
The Guidance Memo provides sample applications of the three-
prong inquiry, most notably to the Prometheus patents themselves.80 
The Prometheus invention would pass inquiries 1 and 2, since as 
discussed in Part II.B, the correlation of thiopurine dosage to red 
blood cells comprised (1) a process and (2) the use of a law of 
 
72. See 2012 Guidance Memo, supra note 68 (noting that the memo is 
applicable in examining all patents that include “process claims in which 
a law of nature, a natural phenomenon, or [a] naturally occurring 
relation or correlation . . . is a limiting element or step”). 
73. Id. at 3. 
74. Id. 
75. 2012 Guidance Memo, supra note 68 (stating that “[p]rocess claims that 
do not include a law of nature, a natural phenomenon, or [a] naturally 
occurring relation or correlation as a claim limitation” should continue 
to be examined in light of their subject matter eligibility under Bilski v. 
Kappos).  
76. Id. at 3. 
77. It is crucial to note the difference between “eligible subject matter” 
under § 101 and the novelty, nonobviousness, and substantive filing 
requirements that govern an inventor’s ability to actually be granted a 
patent. See supra text accompanying notes 7–12. 
78. 2012 Guidance Memo, supra note 68, at 3. 
79. Id. at 4. 
80. Id. at 8. 
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nature.81 However, if the Prometheus patent applications were 
considered by an examiner today, under the new guidance rules, the 
inventor would be barred from patenting under inquiry 3.82 This is 
because, as noted by the Court, the Prometheus patents essentially 
present a law of nature with the general instructions “to apply the 
laws in question.”83 Patentable subject matter requires additional 
steps so that the invention amounts to substantially more than a 
recitation of a natural principle.84 
B. Will the Federal Circuit Acquiesce to the Mayo Holding? 
Following the Mayo decision, the Supreme Court vacated and 
remanded two cases to the Federal Circuit for reconsideration of their 
subject matter patentability in light of the Court’s holding. The first 
case, WildTangent, Inc. v. Ultramercial, LLC,85 has not yet been 
reheard by the Federal Circuit. The § 101 inquiry at issue in 
Ultramercial is the eligibility of a patent covering a method of 
distributing copyrighted material, such as songs or movies, over the 
Internet in exchange for a consumer viewing an advertisement.86 The 
technology relates to the widely-debated issue of patenting software, 
which at first impression seems far removed from the medical field 
and the realm of natural laws. But the now-vacated Ultramercial 
Federal Circuit opinion seemed to tie the principles of Bilski to those 
of Mayo in noting that “[a]lthough abstract principles are not eligible 
for patent protection, an application of an abstract idea may well be 
deserving of patent protection.”87 Thus, the Supreme Court’s decision 
to vacate and remand Ultramercial may indicate an intention to 
extend Mayo’s strict-eligibility requirements for a patent to 
 
81. See id. (defining the relevant analysis for patentability). 
82. See id. (rejecting the example claim “because [it] is directed to non-
statutory subject matter because it is not a patent-eligible practical 
application of a law of nature”).  
83. Mayo Collaborative Servs. v. Prometheus Labs., Inc., 132 S. Ct. 1289, 
1299 (2012). 
84. It is important to note that an initial rejection from an examiner does 
not foreclose future patentability. Thus, the Guidance Memo notes 
potential arguments an applicant may present following an initial 
rejection under the Prometheus three-pronged inquiry. See 2012 
Guidance Memo, supra note 68, at 9 (“It would . . . be proper for the 
applicant to present persuasive arguments that the additional steps add 
something significantly more to the claim than merely describing the 
natural principle. A showing that the steps are not routine, well-known 
or conventional could be persuasive.”). 
85. WildTangent, Inc. v. Ultramercial, LLC, 132 S. Ct. 2431 (2012) (mem.), 
vacating and remanding 657 F.3d 1323 (Fed. Cir. 2011). 
86. Ultramercial, LLC v. Hulu, LLC, 657 F.3d 1323, 1324 (Fed. Cir. 2011). 
87. Id. at 1327 (emphasis added). 
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incorporate an application that is significantly more than reciting a 
law of nature, or, in this case, an abstract idea. 
The second case remanded, Association for Molecular Pathology 
v. Myriad Genetics, Inc., was reheard by the Federal Circuit on 
August 16, 2012, and has far more obvious ties to the Mayo 
decision.88 In essence, the dispute questions three aspects surrounding 
Myriad’s patents over the human genes associated with a person’s 
predisposition to suffer ovarian or breast cancers: Can Myriad patent 
(1) the isolation of the genes, (2) the methods “for comparing DNA 
sequences,” or (3) the process of screening the genes to evaluate 
cancer risk?89 The Myriad case has been closely followed not 
necessarily for the intricacies of its § 101 arguments, but 
predominantly because of the moral and political debates surrounding 
the concept of patenting human genes.90  
The New York Times noted that Myriad’s stock dropped 
immediately following the Mayo decision, based on investors’ fears 
that the company’s gene patents would be reconsidered as laws of 
nature and thus invalid.91 But in spite of the Supreme Court’s holding 
in Mayo, the Federal Circuit in Myriad held that “Mayo does not 
control the question of patent-eligibility” of the Myriad patents, 
because the “isolated DNA molecules before us are not found in 
nature . . . [t]hey are obtained in the laboratory and are man-made, 
the product of human ingenuity.”92 The court held that the patents 
consisted of compositions of matter, which in general are a “thing” 
rather than a Mayo-type law of nature or a Bilski-type abstract idea. 
Therefore, the Federal Circuit upheld the validity of Myriad’s gene 
 
88. Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 
(2012) (mem.), vacating and remanding 653 F.3d 1329 (Fed. Cir. 2011).  
89. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office 
(Myriad), 689 F.3d 1303, 1324 (Fed. Cir. 2012). 
90. See, e.g., Brief of Amici Curiae Rosetta Genomics, Ltd. et al. in 
Support of Defendants-Appellants, Supporting Reversal at 2, Myriad, 
689 F.3d 1303, 1324 (Fed. Cir. 2012) (No. 2010-1406), 2010 WL 4853324 
at *2 (“This case has generated significant public comment regarding so 
called ‘gene patents.’ The ACLU and Plaintiffs-Appellees have 
welcomed, and in fact encouraged, the public attention and resulting 
controversy.”); Daniel Fisher, D.C. Court Upholds Myriad Breast-
Cancer Patents, Snubbing Supreme Court, Forbes (Aug. 16, 2012, 2:23 
PM), http://www.forbes.com/sites/danielfisher/2012/08/16/d-c-court-
upholds-myriad-breast-cancer-patents-snubbing-supreme-court (“Human 
DNA is a natural entity . . . [i]t does not belong to any one company.” 
(quoting American Civil Liberties Union staff attorney Chris Hansen)). 
91. Liptak, supra note 29, at B3. The Federal Circuit had earlier upheld 
two patents held by Myriad Genetics claiming the process of analyzing 
extracted DNA for the genes BRCA1 and BRCA2, in which mutations 
indicate a risk of developing breast or ovarian cancers. Id.  
92. Myriad, 689 F.3d at 1325. 
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patents without a truly comprehensive consideration of Mayo’s 
precedent.93 
Thus, the Federal Circuit in essence has defined human DNA to 
be outside the realm of natural laws.94 But Judge Moore’s concurring 
opinion raised a question: “Does the isolation process change the DNA 
from an unpatentable manifestation of nature into a patentable 
composition of matter?” Judge Moore went on to suggest that the 
task of addressing such complicated scientific principles is better left 
to Congress than the Court.95 The Federal Circuit judges did not 
reach a collective opinion in Myriad, and the holding has been noted 
as a veritable “snub” to the Supreme Court’s Mayo decision.96 But 
just as the Prometheus patents were twice upheld by the Federal 
Circuit before being defeated in the Supreme Court, commentators 
predict that the Myriad case may reach the Court in an upcoming 
term, perhaps with a very different outcome.97 
Conclusion 
The Mayo dispute was unquestionably controversial and garnered 
several amici curiae briefs on each side.98 The Court noted that medical 
experts strongly opposed patentability because of the ever-present 
concern of undue monopolization and the risk of “disproportionately 
tying up the use of . . . underlying natural laws,” which would inhibit 
medical researchers from making further discoveries.99   
93. Id. 
94. See id. at 1331 (“The remand of this case for reconsideration in light of 
Mayo might suggest . . . that the composition claims are mere reflections 
of a law of nature. Respectfully, they are not . . . [t]hey are the products 
of man, albeit following, as all materials do, laws of nature.”). 
95. Id. at 1340, 1345 (Moore, J., concurring). 
96. Fisher, supra note 90. 
97. See id. (“There’s still a great deal of uncertainty because the Supreme 
Court has not had the final word on this issue.” (quoting Antoinette 
Konski, an intellectual property attorney at Foley and Lardner in Palo 
Alto, California)); Jonathan Stempel, Myriad Wins Gene Patent Ruling 
from US Appeals Court, Reuters (Aug. 16, 2012), http://www. 
reuters.com/article/2012/08/16/us-myriad-patent-idUSBRE87F12K2012 
0816 (“Although the decision will probably be appealed to the U.S. 
Supreme Court . . . today . . . the decision is ‘a win.’” (quoting biotech 
patent attorney Tim Worral of Dorsey and Whitney)). 
98. The Court cited the following organizations by name: the American 
Medical Association, the American College of Medical Genetics, the 
American Hospital Association, the American Society of Human 
Genetics, the Association of American Medical Colleges, and the 
Association for Molecular Pathology. Mayo Collaborative Servs. v. 
Prometheus Labs., Inc., 132 S. Ct. 1289, 1304–05 (2012). 
99. Id. at 1294. 
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While most patent applications present a tangible invention or 
“thing” and easily traverse the § 101 threshold, recent advancements 
in the biological and computer sciences have necessitated a thorough 
reexamination of our ability to patent “anything under the sun that is 
made by man.”100 The Supreme Court’s years of silence on subject 
matter eligibility prior to Bilski and Mayo resulted in glaring 
inconsistencies among patent examiners, district courts, and the 
Federal Circuit, which have weakened the integrity of the statutory 
language. But now the Supreme Court and the USPTO have begun to 
take proactive measures to redefine the outer boundaries of patent-
eligible subject matter. Perhaps Ultramercial, along with a potential 
future appeal in Myriad, will resolve the remaining inconsistent 
approaches to applying § 101 doctrine.  
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